| Identification | Back Directory | [Name]
CMX 001 | [CAS]
444805-28-1 | [Synonyms]
CMX 001
HDP-CDV
CS-2275
HDP-HPMPC
HDP-cidofovir
Brincidofovir
CMX001(Brincidofovir)
Brincidofovir (CMX001)
Hexadecyloxypropyl-cidofovir
Brincidofovir, CMX-001, HDP-CDV
Brincidofovir (CMX001, HDP CDV, HDPCDV)
HDP-CDV; HDP-HPMPC;CMX001; BRINCIDOFOVIR; HDP-CIDOFOVIR;CMX 001
CMX001;CMX 001;CMX-001;HDP-CIDOFOVIR;HEXADECYLOXYPROPYL-CIDOFOVIR
CMX 001 1-(hydroxymethyl)ethoxy]methyl]phosphonic acid mono[3-(hexadecyloxy)propyl] ester
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
[[(S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid mono[3-(hexadecyloxy)propyl] ester
(S)-[2-(4-amino-2-oxo-1,2-dihydro-1-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methylphosphonic acid 3-(hexadecyloxy)propyl monoester
Phosphonic acid, P-[[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-, mono[3-(hexadecyloxy)propyl] ester | [Molecular Formula]
C27H52N3O7P | [MDL Number]
MFCD09970716 | [MOL File]
444805-28-1.mol | [Molecular Weight]
561.69 |
| Chemical Properties | Back Directory | [Melting point ]
> 177° C (dec.) | [Boiling point ]
688.6±65.0 °C(Predicted) | [density ]
1.17±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly, Sonicated), Ethanol (Slightly, Heated, Sonicated), Methanol (Sli | [form ]
Solid | [pka]
2.40±0.10(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic | [InChIKey]
WXJFKKQWPMNTIM-VWLOTQADSA-N | [SMILES]
P(CO[C@H](CO)CN1C(=O)N=C(N)C=C1)(=O)(O)OCCCOCCCCCCCCCCCCCCCC |
| Hazard Information | Back Directory | [Uses]
Brincidofovir is an antiviral inhibitor, working against BK polymavirus replication in primary human urothelial cells. Cytostatic, cytotoxic agent. | [Biological Activity]
cmx001 is a broad spectrum antiviral agent [1].cmx001 has been reported to be active in vitro against a broad range of viruses from all five families of dsdna viruses infecting human with ec50 values of 0.02μm, 0.0004μm, 17μm , 0.045μm and 0.07μm for adenovirus, herpesvirus, papillomavirus, polyomavirus and orthopoxvirus, respectively. in addition, cmx001 has been revealed to arrest disease progression by inhibiting viral dna replication and thereby reducing viral burden. apart from these, initial studies has been demonstrated the efficacy of cmx001 for pre-exposure and post-exposure prophylaxis in mouse, rabbit, cynomolgus monkeys and human [1]. | [in vivo]
Brincidofovir (BCV) (20 mg/kg; p.o.; on days 1, 3, 5, 7, 10, 14, 17, 21, and 24) extends survival in immune-deficient BALB/c nu/nu mice following lethal challenge with IHD-J-Luc VACV[3]. | Animal Model: | BALB/c nu/nu mice (infected with IHD-J-Luc VACV)[3] | | Dosage: | 20 mg/kg | | Administration: | P.o.; on days 1, 3, 5, 7, 10, 14, 17, 21, and 24 | | Result: | On days 1, 3, and 5 maintained their weights initially but started to lose weight beginning on day 9 and succumbed between days 24 and 29 postchallenge.
|
| [storage]
Store at -20°C | [References]
[1]lanier r1, trost l, tippin t, lampert b, robertson a, foster s, rose m, painter w, o'mahony r, almond m, painter g.development of cmx001 for the treatment of poxvirus infections. viruses. 2010 dec; 2(12):2740-2762. |
|
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|